EP
CRL icon

Essential Partners’s Charles River Laboratories CRL Stock Holding History

Essential Partners’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.76K Hold
21
– – ﹤0.01% 1567
2026
Q1 		$3.62K Sell
21
-127
-86% -$23.5K ﹤0.01% 1737
2025
Q4 		$29.5K Hold
148
– – 0.01% 771
2025
Q3 		$23.2K Buy
+148
New +$23.5K 0.01% 844

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Essential Partners's CRL Position: Q2 2026 in Review

Essential Partners held its Charles River Laboratories (CRL) position steady in Q2 2026 at 21 shares worth $4.76K. The position accounts for ﹤0.01% of the portfolio, ranked #1567.

Essential Partners first reported a position in CRL in Q3 2025 and has held it in 4 quarters since. The position peaked at $29.5K in Q4 2025. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Essential Partners held 21 shares of Charles River Laboratories worth $4.76K as of Q2 2026.
  • Essential Partners left its Charles River Laboratories share count unchanged in Q2 2026.
  • Charles River Laboratories made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1567 holding.
  • Essential Partners first reported a position in Charles River Laboratories in Q3 2025 and has held it in 4 quarters since.
  • Essential Partners's Charles River Laboratories position peaked at $29.5K in Q4 2025.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.